000			03869nam a22003735i 4500
999			_c80407 _d80407 _x1
001			80407
003			ES-MaUEC
005			20230202102558.0
007			cr nn 008mamaa
008			140423s2014 gw | s |||| 0|eng d
020			_a9783319051048
024	7		_a10.1007/978-3-319-05104-8 _2doi
040			_dES-MaUEC
050		4	_aRC271.I45 _bC363 2014
245	1	0	_aCancer Immunotherapy Meets Oncology : _bIn Honor of Christoph Huber _cedited by Cedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammensee.
260			_aCham, Switzerland _bSpringer International Publishing _c2014
300			_a1 recurso en línea (XX, 246 p.) _b19 ilustraciones, 18 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aImmunological and Regulatory Framework for Immuno-Oncology: From Basic Immunology to New Therapies for Patients -- How T cells single out tumor cells: 'and that has made all the difference' -- Tregs and Immune Inhibition -- Regulatory Landscape for Cancer Immunotherapy -- Immunoguiding -- Onco-Immunology Framework and Immunomodulatory Antibodies -- Immunotherapies:Â{u0970}tide-based Vaccines and HPV Malignancies.-Â{u496E}ndritic cell based cancer vaccines.-Â{u2381} Vaccines and Personalized Medicine Approaches.-Antibody Therapy in Oncology.-Â{u5BA7}gineered Antibodies to Engage Immune Cells to the Tumor -- TCRs and TCR Therapy -- CAR Therapy.-Â{u386E}ncer Entities: Melanoma -- Prostate Cancer/Sipuleucel and RNA Vaccines -- Recent advances in the immunotherapy of renal cell cancer and other solid tumors -- Gastric Cancer -- NSCLC -- Breaking tolerance by allogeneic lymphocyte therapy.-Â{u2A6F}omarkers: Exploring Immunogenic Cell Death for Patient Benefit -- Circulating Tumor Cells -- Genomics Meets Oncology -- Featured Chapters: Oncolytic Viruses -- Pharma View on Immunotherapy -- Final Remarks.
520			_aThis book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Âáncer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
650		7	_2embne _9145440 _aInmunoterapia
700	1		_aBritten, Cedrik Michael _eeditor literario _988547 _0Local
700	1		_aKreiter, Sebastian _eeditor literario _988548 _0Local
700	1		_aDiken, Mustafa _eeditor literario _988549 _0Local
700	1		_aRammensee, Hans-Georg _eeditor literario _988550 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-05104-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12881600 _b10-10-17 _c11-11-15
942			_2lcc _cLE
945			_aRC271.I45 C363 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11561427 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b11-11-15 _cm _dz _e- _feng _ggw _h0